The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples. We also highlight what we see as the shared responsibility of manufacturers or vendors, regulators, healthcare systems, medical physicists, and clinicians to enact appropriate testing and oversight to ensure a safe and equitable transformation of medicine through AI.
Artificial intelligence in medicine: mitigating risks and maximizing benefits via quality assurance, quality control, and acceptance testing / Mahmood, Usman; Shukla-Dave, Amita; Chan, Heang-Ping; Drukker, Karen; Samala, Ravi K; Chen, Quan; Vergara, Daniel; Greenspan, Hayit; Petrick, Nicholas; Sahiner, Berkman; Huo, Zhimin; Summers, Ronald M; Cha, Kenny H; Tourassi, Georgia; Deserno, Thomas M; Grizzard, Kevin T; Näppi, Janne J; Yoshida, Hiroyuki; Regge, Daniele; Mazurchuk, Richard; Suzuki, Kenji; Morra, Lia; Huisman, Henkjan; Armato, Samuel G; Hadjiiski, Lubomir. - 1:1(2024). [10.1093/bjrai/ubae003]
Artificial intelligence in medicine: mitigating risks and maximizing benefits via quality assurance, quality control, and acceptance testing
Morra, Lia;
2024
Abstract
The adoption of artificial intelligence (AI) tools in medicine poses challenges to existing clinical workflows. This commentary discusses the necessity of context-specific quality assurance (QA), emphasizing the need for robust QA measures with quality control (QC) procedures that encompass (1) acceptance testing (AT) before clinical use, (2) continuous QC monitoring, and (3) adequate user training. The discussion also covers essential components of AT and QA, illustrated with real-world examples. We also highlight what we see as the shared responsibility of manufacturers or vendors, regulators, healthcare systems, medical physicists, and clinicians to enact appropriate testing and oversight to ensure a safe and equitable transformation of medicine through AI.| File | Dimensione | Formato | |
|---|---|---|---|
| ubae003.pdf accesso aperto 
											Tipologia:
											2a Post-print versione editoriale / Version of Record
										 
											Licenza:
											
											
												Creative commons
												
												
													
													
													
												
												
											
										 
										Dimensione
										1.45 MB
									 
										Formato
										Adobe PDF
									 | 1.45 MB | Adobe PDF | Visualizza/Apri | 
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11583/2986583
			
		
	
	
	
			      	